Literature DB >> 8808855

Upper tract tumors in patients with primary bladder cancer followed for 15 years.

H W Herr1, M S Cookson, S M Soloway.   

Abstract

PURPOSE: We evaluated the long-term incidence of upper tract tumors in patients with primary superficial bladder cancer.
MATERIALS AND METHODS: A total of 86 patients with stages Ta, T1 and Tis bladder tumors, who were entered into a prospective trial of bacillus Calmette-Guerin between 1978 and 1981, was followed for 15 years or longer.
RESULTS: Of the 86 patients 18 (21%) had upper tract tumors after a median interval of 7.3 years (range 1 to 15). Tumors occurred within 5 years of followup in 6 cases, between 5 and 10 years in 7, and between 10 and 15 years in 5. The majority of cancers were invasive and 7 patients died of upper tract tumors.
CONCLUSIONS: Patients with primary bladder tumors are at risk for upper urinary tract disease for up to 15 years, which suggests the need for lifelong regular upper tract monitoring in these cases.

Entities:  

Mesh:

Year:  1996        PMID: 8808855

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Kirk A Keegan; Matthew J Resnick; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

2.  Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?

Authors:  Thomasz Golabek; Joan Palou; Oscar Rodríguez; Josep Maria Gaya; Alberto Breda; Humberto Villavicencio
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

3.  Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Authors:  Nathan Perlis; Polat Turker; Peter J Bostrom; Cynthia Kuk; Tuomas Mirtti; Girish Kulkarni; Neil E Fleshner; Michael A S Jewett; Antonio Finelli; Alexandre R Zlotta
Journal:  World J Urol       Date:  2012-07-19       Impact factor: 4.226

4.  Multidetector-row computed tomography (MDCT) in patients with a history of previous urothelial cancer or painless macroscopic haematuria.

Authors:  Ullrich G Mueller-Lisse; Ulrike L Mueller-Lisse; Josef Hinterberger; Peter Schneede; Thomas Meindl; Maximilian F Reiser
Journal:  Eur Radiol       Date:  2007-04-03       Impact factor: 5.315

5.  The influence of post-diuretic late phase imaging in visual and quantitative evaluation of urothelial tumors by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zehra Pınar Koç; Pelin Özcan Kara; Emel Sezer; Kadir Eser
Journal:  Turk J Urol       Date:  2019-12-01

6.  The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience.

Authors:  Lamont J Barlow; James M McKiernan; Mitchell C Benson
Journal:  World J Urol       Date:  2009-02-13       Impact factor: 4.226

7.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

8.  Simultaneous Cystectomy and Nephroureterectomy due to Synchronous Upper Urinary Tract Tumors and Invasive Bladder Cancer: Open and Laparoscopic Approaches.

Authors:  Manuel Pérez-Utrilla Pérez; Alfredo Aguilera Bazán; José M Alonso Dorrego; Rebeca Vitón Herrero; Jesús Cisneros Ledo; Javier de la Peña Barthel
Journal:  Curr Urol       Date:  2012-09-27

Review 9.  [Renal pelvic carcinoma: a different urothelial tumor?].

Authors:  F Hofstädter
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

10.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.